Bromide

Bromide

SCHEMBL309594

Br.CCCCC(N)(CCCC)CCCC

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FDPS P14324 3/20 0.44
DNM1 Q05193 4/20 0.38
TSHR P16473 3/20 0.38
LMNA P02545 1/20 0.38
SMPD1 P17405 2/20 0.36
THRB P10828 1/20 0.35
TNNC1 P63316 5/20 0.33
SGPL1 O95470 1/20 0.33
S1PR4 O95977 1/20 0.33
S1PR1 P21453 1/20 0.33
GPR183 P32249 1/20 0.33
CERS2 Q96G23 1/20 0.33
S1PR3 Q99500 1/20 0.33
S1PR5 Q9H228 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL93609 0.97 FDPS (0.46) FDPSDNM1TSHRLMNASMPD1
Bromide SCHEMBL4472153 0.94 FDPS (0.41) FDPSDNM1TSHRLMNASMPD1
Bromide SCHEMBL3842068 0.94 FDPS (0.44) FDPSDNM1TSHRSMPD1THRB
Iodide SCHEMBL553007 0.93 FDPS (0.44) FDPSDNM1TSHRLMNASMPD1
Water SCHEMBL661747 0.93 FDPS (0.44) FDPSDNM1TSHRLMNASMPD1
Fluoride SCHEMBL4871826 0.93 FDPS (0.44) FDPSDNM1TSHRLMNASMPD1
Hydrochloric Acid SCHEMBL363004 0.93 FDPS (0.44) FDPSDNM1TSHRLMNASMPD1
SCHEMBL3643521 0.90 FDPS (0.42) FDPSDNM1TSHRLMNASMPD1
SCHEMBL346990 0.90 FDPS (0.46) FDPSDNM1TSHRSMPD1THRB
SCHEMBL516377 0.90 FDPS (0.42) FDPSDNM1TSHRLMNASMPD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260015560-A1 COMPOSITIONS FOR POST-CMP CLEANING OF MICROELECTRONIC DEVICES ENTEGRIS INC (US) 2026-01-15 US claimed
CN-113441178-B TiO 2 Application of SAPO-5 catalyst in preparation of cycloalkyl-substituted aromatic hydrocarbon by using low-carbon alkylating agent and method thereof 西北大学 2023-05-09 CN claimed
CN-115368477-A Preparation method of carboxyl maltose iron with high yield and high iron content 武汉科福新药有限责任公司 2022-11-22 CN claimed
US-11434201-B2 Processes for preparing pyrrolidine compounds VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-09-06 US claimed
CN-112552517-B Hyperbranched polymer viscosity reducer for high-strength concrete and preparation method thereof 中建西部建设建材科学研究院有限公司 2022-04-01 CN claimed
EP-3661915-B1 PROCESSES FOR PREPARING PYRROLIDINE COMPOUNDS VERTEX PHARMA (US) 2022-03-09 EP claimed
CN-113441178-A TiO2Application of/SAPO-5 catalyst in preparation of cycloalkyl substituted aromatic hydrocarbon by low-carbon alkylating agent and method 西北大学 2021-09-28 CN claimed
CN-113372549-A Vinyl-terminated hyperbranched polymer, viscosity-reducing polycarboxylate superplasticizer with hyperbranched structure and preparation method of viscosity-reducing polycarboxylate superplasticizer 中建西部建设建材科学研究院有限公司 2021-09-10 CN claimed
US-20210246117-A1 PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS (SAN DIEGO) LLC 2021-08-12 US claimed
CN-112552517-A Hyperbranched polymer viscosity reducer for high-strength concrete and preparation method thereof 中建西部建设建材科学研究院有限公司 2021-03-26 CN claimed
CN-111051280-A Process for producing pyrrolidine compound 弗特克斯药品有限公司 2020-04-21 CN claimed
CN-108219128-B Preparation method of cement dispersant with sulfate adaptability and viscosity reduction effect 江苏苏博特新材料股份有限公司 2019-12-27 CN claimed
WO-2019113476-A2 PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2019-06-13 WO claimed
WO-2019028228-A1 PROCESSES FOR PREPARING PYRROLIDINE COMPOUNDS VERTEX PHARMACEUTICALS INCORPORATED (US) 2019-02-07 WO claimed
US-9522915-B2 Method for preparing an important intermediate of linagliptin 2Y-CHEM, LTD. (CN) 2016-12-20 US claimed
US-20150274728-A1 METHOD FOR PREPARING AN IMPORTANT INTERMEDIATE OF LINAGLIPTIN 2Y-CHEM, LTD. (CN) 2015-10-01 US claimed
US-20090253746-A1 Synthesis and Preparations of Intermediates and New Polymorphs Thereof Useful For The Preparation Of Donepezil Hydrochlcoride MEDICHEM S.A. (ES) 2009-10-08 US claimed
EP-1960357-A2 SYNTHESIS AND PREPARATIONS OF INTERMEDIATES AND POLYMORPHS THEREOF USEFUL FOR THE PREPARATION OF DONEPEZIL HYDROCHLORIDE Medichem S.A. (ES) 2008-08-27 EP claimed
WO-2007119118-A2 SYNTHESIS AND PREPARATIONS OF INTERMEDIATES AND POLYMORPHS THEREOF USEFUL FOR THE PREPARATION OF DONEPEZIL HYDROCHLORIDE MEDICHEM S.A. (US) 2007-10-25 WO claimed
US-4487722-A Method of preparing 4-(α-hydrocarbyl-α-cyanomethyl)2,6-di-substituted phenols ETHYL CORPORATION (US) 1984-12-11 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210246117-A1 PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1B, SCNN1G FDPS 185/4885DNM1 943/4885TSHR 2590/4885
US-20150274728-A1 METHOD FOR PREPARING AN IMPORTANT INTERMEDIATE OF LINAGLIPTIN DPP4, DPP9, DPP3 FDPS 1255/4885DNM1 4278/4885TSHR 3222/4885
US-11434201-B2 Processes for preparing pyrrolidine compounds MTAP, PRMT5, TET3 FDPS 650/4885DNM1 201/4885TSHR 1970/4885
US-20260015560-A1 COMPOSITIONS FOR POST-CMP CLEANING OF MICROELECTRONIC DEVICES TET2, ASIC1, PIEZO1 FDPS 4294/4885DNM1 2538/4885TSHR 2647/4885
US-20090253746-A1 Synthesis and Preparations of Intermediates and New Polymorphs Thereof Useful For The Preparation Of Donepezil Hydrochlcoride CYP2E1, DRD4, COMT FDPS 3192/4885DNM1 107/4885TSHR 4679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.